Skip to main content
OpenTrials
Completed

NCT Number: NCT00363337

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

The specific aim of this study is to obtain preliminary evidence of the acute effectiveness and tolerability of aripiprazole in the treatment of bipolar depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Cincinnati Medical Center

Cincinnati, Ohio, 45267-0559, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have clinical significant depressive symptoms and have failed one or more mood stabilizer trials; may or may not be receiving antimanic or mood stabilizing medications; subjects or legally authorized representative must sign the Informed Consent document after the nature of the trial has been fully explained; if female, subjects must be postmenopausal, surgically incapable of childbearing or practicing medically acceptable effective method(s) of contraception.

Exclusion criteria

  • subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or a psychotic disorder; subjects with serious general medical illness; subjects who are allergic to or have demonstrated hypersensitivity to aripiprazole; women who are pregnant or nursing; subjects who have received an experimental drug or used an experimental device within 30 days; subjects who have a history of neurologic malignant syndrome.

Treatment and study plan

Aripiprazole

Drug

open label treatment with aripiprazole

Other names: Abilify

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    Time frame: per protocol

Secondary outcomes

  1. Clinical Global Impression Scale Modified for Bipolar Illness (CGI-BP)

    Time frame: per protocol

Sponsors and collaborators

Lead sponsor

Lindner Center of HOPE

Other

Collaborators

  • University of Cincinnati

Registry information

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Aug 15, 2006
Registry last updated
Jun 22, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.